SMTL ID : 7tps.2 (1 other biounit)

Crystal structure of ALPN-202 (engineered CD80 vIgD) in complex with PD-L1

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.15 Å

Oligo State

hetero-1-1-mer

Ligands

2 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose

NAG-NAG-FUC.1: 5 residues within 4Å: Chain A: N.55 Chain B: D.31, A.34, Y.100, G.101 No protein-ligand interaction detected (PLIP) NAG-NAG-FUC.2: 5 residues within 4Å: Chain B: N.17, Q.65, R.68, Q.82, T.84 1 PLIP interactions: 1 interactions with chain B Hydrophobic interactions: B:T.84

3 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG.3: 4 residues within 4Å: Chain A: N.19, T.62, N.63, N.64 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:N.63, A:N.64 NAG.4: 6 residues within 4Å: Chain B: E.140, S.166, K.167, R.168, N.174, T.176 4 PLIP interactions: 4 interactions with chain B Hydrophobic interactions: B:R.168 Hydrogen bonds: B:K.167, B:K.167, B:N.174 NAG.5: 4 residues within 4Å: Chain B: E.132, R.180, I.181, N.182 No protein-ligand interaction detected (PLIP)

1 x GOL: GLYCEROL(Non-functional Binders)

GOL.6: 3 residues within 4Å: Chain B: R.68, L.69, K.71 3 PLIP interactions: 3 interactions with chain B Hydrogen bonds: B:R.68, B:L.69, B:K.71

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Maurer, M.F. et al., The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity. Nat Commun (2022)

Release Date

2022-03-16

Peptides

T-lymphocyte activation antigen CD80: A
Programmed cell death 1 ligand 1: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
C

B
D

T-lymphocyte activation antigen CD80

Programmed cell death 1 ligand 1

Related Entries With Identical Sequence